# PROJECT GOALS â€” stroke_hc_v8_2 ë…¼ë¬¸ ë¶„ì„ ê³„íš

> ìƒì„±ì¼: 2026-02-16 | ëª©ì : ë…¼ë¬¸ êµ¬ì„±ì— í•„ìš”í•œ ë¶„ì„ í•­ëª© ëª…ì‹œ ë° ë‹¬ì„± ì¶”ì 

## ì—°êµ¬ ì§ˆë¬¸ (Research Questions)

1. **Strokeê°€ PBMC ë©´ì—­ landscapeë¥¼ ì–´ë–»ê²Œ ë°”ê¾¸ëŠ”ê°€?** (HC vs IS)
2. **ê°™ì€ IS í™˜ì ì¤‘ ì™œ ì–´ë–¤ í™˜ìëŠ” ì˜ˆí›„ê°€ ë‚˜ìœê°€?** (g3==1 Good vs g3==2 Bad)
3. **HC vs IS ì°¨ì´ì™€ Good vs Bad ì°¨ì´ì˜ ê³µí†µ ë©´ì—­ ê¸°ì „ì´ ì¡´ì¬í•˜ëŠ”ê°€?** (Cross-layer)
4. **í•µì‹¬ ë©´ì—­ ë³€í™”ë¥¼ driveí•˜ëŠ” gene signatureëŠ” ë¬´ì—‡ì´ë©°, ì–´ë–¤ ì„¸í¬ê°€ ê´€ì—¬í•˜ëŠ”ê°€?**

---

## ë¶„ì„ í•­ëª© (Analysis Items)

### 1. Pre-processing & Integration

**ëª©ì **: scVI integration + annotation ì™„ë£Œ, ê¹¨ë—í•œ ë¶„ì„ ë°ì´í„° ì¤€ë¹„

| í•­ëª© | ìƒíƒœ | ë¹„ê³  |
|------|------|------|
| CellBender + Souporcell + Solo | âœ… ì™„ë£Œ | Pipeline at mypy_re |
| scVI integration (n_latent=30, batch=GEM) | âœ… ì™„ë£Œ | GPU RTX4090 |
| Clustering (res=2, scvi_snn) | âœ… ì™„ë£Œ | 36 clusters |
| Annotation (anno1 26 types, anno2 8 compartments) | âœ… ì™„ë£Œ | |
| Annotation QC (doublet/LQ/RBC removal) | âœ… ì™„ë£Œ | 21,578 cells removed â†’ 205,277 clean |
| Subset ìƒì„± (5_1_hc_is.qs, 5_2_is_g3.qs) | âœ… ì™„ë£Œ | L1: 131K, L2: 54K |

**ë°ì´í„° íŒŒì¼**: `/data/user3/sobj/stroke_hc_v8_2/5_strokev8_clean.qs`

---

### 2. Descriptive Figures (ë…¼ë¬¸ Figure 1 í›„ë³´)

**ëª©ì **: Integration í’ˆì§ˆ, annotation ê·¼ê±°, ì „ì²´ ë°ì´í„° ê°œìš”ë¥¼ ì‹œê°ì ìœ¼ë¡œ ì œì‹œ

#### 2-1. Integration & Annotation outcome
- [ ] **UMAP** (umap.scvi): anno1 colored, split by cohort (HC/Stroke)
- [ ] **DotPlot**: canonical markers Ã— anno1 â†’ annotation rationale ê·¼ê±°
- [ ] (Optional) UMAP colored by GEM/batch â†’ integration í’ˆì§ˆ í™•ì¸

#### 2-2. Frequency analysis (stacked bar)
- [ ] **Sample-level stacked bar chart**: ëª¨ë“  sample(~100ëª…)ì—ì„œ compartment(anno2) ë¹„ìœ¨
- [ ] **ì •ë ¬ ê¸°ì¤€**: signature score ê°’ ë‚´ë¦¼ì°¨ìˆœ
- [ ] **ì‹œê°ì  ì„¤ê³„**:
  - Monocyte â†’ ë°”ë‹¥ (bottom), T cell â†’ ìœ„ìª½ (top)
  - Scoreê°€ ë†’ì„ìˆ˜ë¡ í•´ë‹¹ compartment ë¹„ìœ¨ì´ ë†’ë‹¤ëŠ” ê²ƒì„ ì‹œê°ì ìœ¼ë¡œ ì•”ì‹œ
- [ ] HC/Stroke ë˜ëŠ” g3 ê·¸ë£¹ë³„ colour band ì¶”ê°€

#### 2-3. Signature score Ã— condition (compartmentë³„)
- [ ] **Compartmentë³„ë¡œ** signature scoreê°€ HC vs Stroke, Good vs Badì—ì„œ ë‹¤ë¥¸ ê²½ìš°ë§Œ ì„ ë³„
- [ ] **Visualization**: boxplot + VlnPlot overlay
- [ ] **Two levels**: cell-level + pseudobulk(patient)-level ë‘˜ ë‹¤ ì œì‹œ
- [ ] í†µê³„ ê²€ì •: Wilcoxon (cell-level), patient-level t-test or mixed model

#### 2-4. Signature gene heatmap
- [ ] Signature scoreë¥¼ êµ¬ì„±í•˜ëŠ” **ê°œë³„ gene**ì˜ ë°œí˜„ê°’ heatmap
- [ ] **Level options**:
  - Patient-level (pseudobulk mean per patient)
  - Compartment Ã— patient level
  - Cell-level (sampled, ë„ˆë¬´ í¬ë©´)
- [ ] HC vs Stroke, Good vs Bad íŒ¨í„´ ì‹œê°ì  í™•ì¸
- [ ] Annotation bar: cohort, g3, anno2 ë“±

#### 2-5. Group-level signature difference
- [ ] Patient-level / compartment-levelì—ì„œ signature ë°œí˜„ëŸ‰ boxplot + VlnPlot
- [ ] HC vs Stroke, Good vs Bad ê°ê°
- [ ] í†µê³„ ê²€ì • í¬í•¨ (p-value annotation)

#### 2-6. Cross-layer overlap (HC-vs-IS âˆ© Good-vs-Bad)
- [ ] HC vs Stroke DEG/signatureì™€ Good vs Bad DEG/signatureì˜ overlap
- [ ] **Venn diagram** ë˜ëŠ” **UpSet plot**
- [ ] Enrichment: shared genesì˜ pathway/function ë¶„ì„
- [ ] í•µì‹¬ ì§ˆë¬¸: "Stroke responseì™€ bad outcomeì˜ ë©´ì—­ ê¸°ì „ì´ ê²¹ì¹˜ëŠ”ê°€?"

**ì „ì œ ì¡°ê±´**: FGS/TML ê²°ê³¼, DEG consensus ê²°ê³¼ í•„ìš”

---

### 3. (ë²ˆí˜¸ ê±´ë„ˆëœ€ â€” 2ë²ˆì— í†µí•©)

---

### 4. Frequency Analysis (Detail)

**ëª©ì **: HC vs Stroke, Good vs Badì—ì„œ ì°¨ì´ ë‚˜ëŠ” cell typeì„ robustí•˜ê²Œ identify

| ë°©ë²• | ìƒíƒœ | ë¹„ê³  |
|------|------|------|
| **MASC** | âœ… ì™„ë£Œ | 6 comparisons (3 cluster levels Ã— 2 comparisons) |
| **scCODA** | âœ… ì™„ë£Œ | L1: 14/21 credible, L2: CD14+ Mono only |
| **MILO** | âœ… ì™„ë£Œ | L1: 11,739 nhoods (63% sig), L2: 4,664 nhoods (19% sig) |
| **MELD** | ğŸ”² ë¯¸ì‹œì‘ | Python, density estimation approach |
| **scANVI** | ğŸ”² ë¯¸ì‹œì‘ | Cell type prediction + label transfer |

#### MILO Results Summary

**L1 (HC vs IS)**: 14/19 cell types DA by â‰¥2 methods (MILOÃ—MASCÃ—scCODA)
- HC-enriched (11): ISG+ T_cell, Platelet/PLA, CD16+ Mono, pDC, CD8+ Cyto, MAIT, NK, cDC2, Treg, CD8+ Trm, Infl. Mono
- IS-enriched (3): ISG+ Myeloid, B_cell, CD14+ Mono
- MILOâ€“MASC direction correlation: Spearman rho=0.53, p=0.02

**L2 (g3 Good vs Bad)**: Only CD14+ Monocyte shows strong DA (MILO + scCODA concordant)
- CD14+ Mono: logFC=2.62, 57% of nhoods enriched in g3=2 (Bad)

- [x] 3ê°€ì§€ ë°©ë²•ìœ¼ë¡œ frequency DA ìˆ˜í–‰ (MASC, scCODA, MILO) âœ…
- [x] Concordance heatmap + scatter plot ìƒì„± âœ…
- [ ] MELD, scANVI (optional)

**ìŠ¤í¬ë¦½íŠ¸ ìœ„ì¹˜**:
- MASC: `Git_Repo/_wt/masc/scripts/masc/run_masc.R`
- MILO: `stroke_hc_v8_2/scripts/run_milo.R`
**ì¶œë ¥**: `/data/user3/sobj/stroke_hc_v8_2/milo/`

---

### 5. CCI (Cell-Cell Interaction) Results

**ëª©ì **: HC vs Stroke, Good vs Badì—ì„œ ì„¸í¬ ê°„ ì†Œí†µ íŒ¨í„´ ì°¨ì´ ê·œëª…

#### í˜„ì¬ ê²°ê³¼ ìš”ì•½

| ë¶„ì„ | Layer | ê²°ê³¼ | ìƒíƒœ |
|------|-------|------|------|
| CellChat L1 | HC vs IS | Stroke -37% interaction (SIIS) | âœ… ì™„ë£Œ |
| CellChat L2 | Good vs Bad | Bad +10% interaction, Monoâ†’DC/Bc ì¦ê°€ | âœ… ì™„ë£Œ |
| MNN L1 | HC vs IS | group_prioritization ë¹ˆ í…Œì´ë¸” (anno2 too coarse) | âš ï¸ ì¬ì‹¤í–‰ í•„ìš” |
| MNN L2 | Good vs Bad | ë™ì¼ ë¬¸ì œ | âš ï¸ ì¬ì‹¤í–‰ í•„ìš” |

#### ì¶”ê°€ í•„ìš” ë¶„ì„

- [ ] **MNN re-run at anno1** (26 types): DEê°€ ì œëŒ€ë¡œ ë‚˜ì˜¤ë„ë¡ ì„¸ë¶„í™”
- [ ] **Circos plot** (ë©”ì¸): ì£¼ìš” condition-specific LR pair ì‹œê°í™”
- [ ] **Incoming vs Outgoing** analysis: ì–´ë–¤ cell typeì´ sender/receiverë¡œ ë³€í™”í•˜ëŠ”ê°€
- [ ] **Ligand/Receptor level** analysis: ì–´ë–¤ cellì—ì„œ ì–´ë–¤ signaling moleculeì„ ë§ì´ ë°œí˜„?
  - ì‹¤ì œ DEGì— í•´ë‹¹í•˜ëŠ”ê°€?
  - ê·¸ë£¹ ê°„ ì°¨ì´ê°€ ì‹¤ì œë¡œ ë‚˜ëŠ”ê°€?
- [ ] **Cell count bias control**: ì „ì²´ ì„¸í¬ ìˆ˜ ì°¨ì´ì— ì˜í•œ í¸í–¥ ë³´ì •
  - CellChatì˜ `population.size = TRUE` ì˜µì…˜
  - ë˜ëŠ” downsampling í›„ ì¬ì‹¤í–‰
- [ ] **Correlation scatter plot** (optional):
  - ì˜ˆ: ì„¸í¬ ë‚´ TXNIP Ã— CXCL8 ë°œí˜„ correlation
  - ë˜ëŠ” Aì„¸í¬ TXNIP â†’ Bì„¸í¬ CXCL8 inter-cellular correlation
  - Pseudobulk levelë¡œ ê³„ì‚°í•˜ë©´ patient ìˆ˜ì¤€ ìƒê´€ê´€ê³„

**ìŠ¤í¬ë¦½íŠ¸ ìœ„ì¹˜**:
- CellChat: `Git_Repo/_wt/cellchat/scripts/cellchat/run_cellchat_cli.R`
- MNN: `Git_Repo/_wt/cci/scripts/cci/mnn/run_multinichenet.R`
- CCI plots: `/data/user3/sobj/stroke_hc_v8_2/scripts/run_cci_plots.sh`

**ì¶œë ¥ ìœ„ì¹˜**: `/data/user3/sobj/stroke_hc_v8_2/cci/`

---

### 6. Pathway Analysis

**ëª©ì **: DEG ê¸°ë°˜ functional enrichmentë¡œ ìƒë¬¼í•™ì  ì˜ë¯¸ ë¶€ì—¬

- [ ] **Gene set**: HALLMARK, KEGG, Reactome, GO-BP
- [ ] **Method**: fgsea / clusterProfiler (ORA + GSEA)
- [ ] **Input**: DEG consensus ê²°ê³¼ (multi-method), FGS signature genes
- [ ] **Comparison**: HC vs Stroke pathway vs Good vs Bad pathway overlap
- [ ] **Visualisation**: dotplot, barplot, network plot (enrichplot)
- [ ] Compartmentë³„ pathway ì°¨ì´ (Mono, CD4, CD8 ë“±)

**ì „ì œ ì¡°ê±´**: DEG Consensus ì™„ë£Œ í•„ìš”

**ìŠ¤í¬ë¦½íŠ¸**: `Git_Repo/_wt/deg-consensus/scripts/consensus/run_deg_consensus_cli.R` + ë³„ë„ enrichment script í•„ìš”

---

### 7. Pseudotime Distribution

**ëª©ì **: ë¶„í™” pseudotime ë¶„í¬ ì°¨ì´ë¡œ ë©´ì—­ ì„¸í¬ maturation ë³€í™” ê·œëª…

#### í˜„ì¬ ê²°ê³¼

| Compartment | g3 p-value | Cohort p-value | í•´ì„ |
|---|---|---|---|
| **Monocyte** | < 2e-16 | < 2e-16 | Stroke/Bad â†’ ì´ˆê¸° pseudotime ì§‘ì¤‘ (ë¶„í™” ì •ì²´) |
| **CD4+ T** | 0.028 | < 2e-16 | ìœ ì‚¬ íŒ¨í„´, effect size ì‘ìŒ |
| **CD8+ T** | TBD | TBD | v2 ì‹¤í–‰ í•„ìš” |

#### ì¶”ê°€ í•„ìš” ë¶„ì„

- [ ] CD8 trajectory v2 ì™„ë£Œ
- [ ] **FeaturePlot + pseudotime overlay**: pseudotime gradientê°€ UMAP ì–´ë””ì— ìœ„ì¹˜?
  - ì–´ëŠ subsetì—ì„œ ì–´ë””ë¡œ ë¶„í™”ê°€ í¼ì ¸ë‚˜ê°€ëŠ”ì§€ ì¶”ë¡ 
  - Canonical marker expressionê³¼ pseudotime ìœ„ì¹˜ ëŒ€ì‘
- [ ] HC vs Strokeì˜ pseudotime ë¶„í¬ ì°¨ì´ â†’ density plot / ridge plot
- [ ] **Branch analysis**: Slingshot lineage branchë³„ condition ë¶„í¬ ì°¨ì´

**ì¶œë ¥**: `/data/user3/sobj/stroke_hc_v8_2/trajectory_v2/`

---

### 8. Pseudotime-dependent Functional Change (Gene Dynamics)

**ëª©ì **: Pseudotimeì— ë”°ë¥¸ ìœ ì „ì ë°œí˜„ ë³€í™”ê°€ HC vs Stroke, Good vs Badì—ì„œ ë‹¤ë¥¸ì§€ ê²€ì¦

#### Gene Dynamics v3 (Batch-corrected GAMM) â€” âœ… ALL COMPLETE

**ëª¨ë¸**: `expr ~ s(pt) + cond + s(pt, by=cond) + offset(log(nCount_RNA)) + percent.mt + s(GEM, bs="re")`
**Family**: NB(log), REML
**Test**: Interaction term `s(pt, by=cond)`ì˜ ìœ ì˜ì„± (Chi-squared ANOVA)

| í•­ëª© | ìƒíƒœ |
|------|------|
| `analyze_gene_dynamics_v2()` í•¨ìˆ˜ | âœ… êµ¬í˜„ ì™„ë£Œ |
| `run_gene_dynamics_v3.R` ì‹¤í–‰ ìŠ¤í¬ë¦½íŠ¸ | âœ… ì™„ë£Œ |
| Mono Ã— g3 + cohort | âœ… ì™„ë£Œ |
| CD4 Ã— g3 + cohort | âœ… ì™„ë£Œ |
| CD8 Ã— g3 + cohort | âœ… ì™„ë£Œ |
| **Effect sizes (ABC/rABC/RMISE)** | âœ… Phase 1-2 ì™„ë£Œ |
| **Lamian validation** | âœ… Phase 3 ì™„ë£Œ |
| **Pseudobulk GAMM sensitivity** | âœ… Phase 4 ì™„ë£Œ |

#### Key Results

| Analysis | GAMM Sig | Lamian Sig | PB Sig | 3-method Consensus |
|----------|----------|------------|--------|--------------------|
| mono/cohort | 21/24 | 14/24 | 16/32 | **10 genes** |
| mono/g3 | 17/23 | 8/23 | 16/30 | ~5 genes |
| cd4/cohort | 20/25 | 13/25 | 10/25 | ~8 genes |
| cd4/g3 | 0/25 | 0/25 | 1/28 | 0 |
| cd8/cohort | 18/23 | 7/23 | 3/25 | ~3 genes |
| cd8/g3 | 1/23 | 0/23 | 0/23 | 0 |

**í•µì‹¬ ë°œê²¬**: Monoê°€ ìœ ì¼í•œ g3 effect compartment; CD8 cell-level ê²°ê³¼ëŠ” pseudoreplication artifact
**ìƒì„¸ ë¬¸ì„œ**: `docs/claude/trajectory/4_TRAJECTORY_RESULTS_INTEGRATED.md`
**ì¶œë ¥**: `trajectory_v3/{analysis,lamian,pseudobulk}/`

---

### 9. FGS/TML: Gene Signature Discovery

**ëª©ì **: HC vs IS, Good vs Badë¥¼ êµ¬ë¶„í•˜ëŠ” gene setì„ ë‹¤ê°ë„ë¡œ ë°œêµ´í•˜ê³ , ê·¸ ìƒë¬¼í•™ì  ì˜ë¯¸ íƒìƒ‰

#### í˜„ì¬ ìƒíƒœ
- n=50 sweep ì‹¤í–‰ ì¤‘ (method 5/10: pca_loadings), then n=100, n=200
- Target: g3 (IS only, 54K cells)
- Control vars: sex, age, GEM

#### ì¶”ê°€ ë¶„ì„ (FGS ì™„ë£Œ í›„)

- [ ] FGS ê²°ê³¼ì˜ **gene overlap** across methods â†’ consensus gene set
- [ ] **Gene expression pattern** í‰ê°€:
  - ì–´ë–¤ cell typeì´ ì£¼ë¡œ ë°œí˜„í•˜ëŠ”ê°€? (DotPlot / heatmap by anno1)
  - Pseudotimeì— ë”°ë¥¸ ë°œí˜„ ì°¨ì´ê°€ ìœ ì˜í•œê°€? (gene dynamics v3 ê²°ê³¼ì™€ êµì°¨)
  - íŠ¹ì • subcelltypeì—ì„œ ë” ë†’ì€ ë°œí˜„? â†’ subclustering í›„ í™•ì¸
- [ ] **Functional role** í•´ì„:
  - ì—¼ì¦ ì§„í–‰(pro-inflammatory)ì— ê´€ì—¬?
  - ë©´ì—­ ì–µì œ(immunosuppressive)ì— ê´€ì—¬?
  - ì–´ë–¤ pathwayì— enriched?
- [ ] HC vs IS signatureì™€ Good vs Bad signatureì˜ ìœ ì‚¬ì„± ë¹„êµ (â†’ Item 10)

#### í•µì‹¬ ì§ˆë¬¸
- ê°€ì¥ ê°•ë ¥í•œ signature signalì€ ë¬´ì—‡ì¸ê°€?
- ì–´ë–¤ geneì´ driveí•˜ëŠ”ê°€?
- ê·¸ geneì€ ê±°ì˜ í•­ìƒ topì— ë‚˜ì˜¤ëŠ”ê°€ (across methods)?
- ë¬´ìŠ¨ cell typeì—ì„œ ë§ì´ ë°œí˜„ë˜ê³ , ì–´ë–¤ ì¼ì„ ì¼ìœ¼í‚¤ë‚˜?
- ì™œ ê·¸ ì„¸í¬ê°€ ëŠ˜ì–´ë‚¬ì„ê¹Œ? ì¦ì‹ì¸ê°€? ì–´ë–»ê²Œ?
  - Cell cycle scoring (Seurat `CellCycleScoring`)
  - Proliferating cell typeì˜ ë¹„ìœ¨ ë³€í™”
  - Growth factor signaling (CCI ê²°ê³¼ ì°¸ì¡°)

**ìŠ¤í¬ë¦½íŠ¸**: `Git_Repo/_wt/fgs/scripts/fgs/run_fgs_pipeline.R`
**ì¶œë ¥**: `/data/user3/sobj/stroke_hc_v8_2/fgs/whole_IS_{50,100,200}/`

---

### 10. Cross-layer Concordance

**ëª©ì **: HC vs IS signatureì™€ Good vs Bad signatureì˜ ìœ ì‚¬ì„± ê²€ì¦

#### í•µì‹¬ ì§ˆë¬¸
- HC vs IS signature â‰ˆ Good vs Bad signatureì¸ê°€?
- ê³µí†µ geneì´ ìˆë‹¤ë©´ â†’ shared immune mechanism
- ì°¨ì´ê°€ ìˆë‹¤ë©´ â†’ Stroke-specific vs outcome-specific pathway

#### ë¶„ì„ ê³„íš
- [ ] **Gene-level overlap**: Venn/UpSet (FGS consensus genes)
- [ ] **Pathway-level overlap**: shared enriched pathways
- [ ] **Effect direction**: ë™ì¼ geneì´ ë™ì¼ ë°©í–¥ìœ¼ë¡œ ë³€í™”í•˜ëŠ”ê°€?
  - Scatter plot: log2FC(HC-vs-IS) Ã— log2FC(Good-vs-Bad)
  - Correlation coefficient + significance
- [ ] **Cell type specificity**: ì–´ë–¤ cell typeì—ì„œ ê³µí†µ ë³€í™”?
- [ ] **Signature transferability**: L1 signatureë¡œ L2 ì˜ˆì¸¡ ê°€ëŠ¥í•œê°€? (ROC/AUC)

---

### 11. External Validation

**ëª©ì **: ì£¼ìš” findingì˜ ì¬í˜„ì„± í™•ì¸

#### í›„ë³´ ì „ëµ
- [ ] **Public scRNAseq stroke data**: GEO/ArrayExpressì—ì„œ ìœ ì‚¬ cohort ê²€ìƒ‰
  - PBMC scRNAseq from stroke patients with outcome data
- [ ] **Bulk RNA-seq validation**: TCGA/GTEx ë“±ì—ì„œ PBMC data í™•ë³´
- [ ] **Signature scoring**: FGS-derived signatureë¥¼ external cohortì— ì ìš©
  - AddModuleScore ë˜ëŠ” AUCell
- [ ] **Clinical correlation**: external cohortì—ì„œ signature score â†” outcome ì—°ê´€ì„±
- [ ] **Cross-species**: (optional) mouse stroke model transcriptomeê³¼ ë¹„êµ

**ì „ì œ ì¡°ê±´**: ëª¨ë“  ì£¼ìš” ë¶„ì„ ì™„ë£Œ, signature gene set í™•ì • í›„

---

## ë¶„ì„ ì˜ì¡´ì„± ê·¸ë˜í”„ (Dependency)

```
1. Pre-processing (âœ…)
   â”œâ”€â”€ 2. Descriptive Figures (âœ… 63 files, ì¶”ê°€ í•„ìš”)
   â”œâ”€â”€ 4. Frequency Analysis
   â”‚     â”œâ”€â”€ MASC (âœ…), scCODA (âœ…), MILO (âœ…)
   â”‚     â””â”€â”€ MELD, scANVI (ğŸ”² optional)
   â”œâ”€â”€ 5. CCI
   â”‚     â”œâ”€â”€ CellChat v2 (âœ… L1+L2)
   â”‚     â””â”€â”€ MNN anno1 (âœ… L1+L2 â€” 78K DEGs, 1.2M ligand activities)
   â”œâ”€â”€ 6. Pathway Analysis (âœ… FGS genes HALLMARK/KEGG/GOBP)
   â”œâ”€â”€ 7. Pseudotime (âœ… v2 all 3 compartments)
   â”œâ”€â”€ 8. Gene Dynamics (âœ… v3 + effect sizes + Lamian + pseudobulk)
   â”œâ”€â”€ 9. FGS/TML (âœ… n=50/100, n=200 ğŸ”„, within-celltype ğŸ”„)
   â”œâ”€â”€ 10. Cross-layer (âœ… DEG concordance 134 genes)
   â””â”€â”€ 11. External Validation (ğŸ”²)
```

---

## ìš°ì„ ìˆœìœ„ (Priority Order)

| ìˆœì„œ | í•­ëª© | ìƒíƒœ | ë¹„ê³  |
|------|------|------|------|
| ~~1~~ | ~~Trajectory v2~~ | âœ… | 3 compartments ì™„ë£Œ |
| ~~2~~ | ~~Gene dynamics v3~~ | âœ… | + effect sizes + Lamian + pseudobulk |
| ~~3~~ | ~~FGS n=50/100~~ | âœ… | n=200 + within-celltype ì§„í–‰ì¤‘ |
| ~~4~~ | ~~MNN anno1~~ | âœ… | L1+L2 ì™„ë£Œ |
| ~~5~~ | ~~DEG Consensus~~ | âœ… | L1: 3 methods, L2: NEBULA only |
| ~~6~~ | ~~scCODA~~ | âœ… | L1: 14/21 credible |
| ~~7~~ | ~~Frequency: MILO~~ | âœ… | L1+L2 ì™„ë£Œ, 3-method concordance |
| 8 | Within-celltype FGS | ğŸ”„ | CD14 Mono ì‹¤í–‰ì¤‘ |
| 9 | cNMF | ğŸ”„ | NK factorizing |
| 10 | Descriptive figures ì¶”ê°€ | ğŸ”² | signature-based plots |
| 11 | External validation | ğŸ”² | ëª¨ë“  ë¶„ì„ í›„ |
